187 related articles for article (PubMed ID: 28056663)
1. Principles for Assessing Adversity in Toxicologic Clinical Pathology.
Ramaiah L; Tomlinson L; Tripathi NK; Cregar LC; Vitsky A; Beust BV; Barlow VG; Reagan WJ; Ennulat D
Toxicol Pathol; 2017 Feb; 45(2):260-266. PubMed ID: 28056663
[TBL] [Abstract][Full Text] [Related]
2. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.
Tomlinson L; Boone LI; Ramaiah L; Penraat KA; von Beust BR; Ameri M; Poitout-Belissent FM; Weingand K; Workman HC; Aulbach AD; Meyer DJ; Brown DE; MacNeill AL; Bolliger AP; Bounous DI
Vet Clin Pathol; 2013 Sep; 42(3):252-69. PubMed ID: 23889060
[TBL] [Abstract][Full Text] [Related]
3. The American Society for Veterinary Clinical Pathology Regulatory Affairs Committee's clinical pathology best practices recommendations will impact the discipline of veterinary toxicologic clinical pathology.
Reagan WJ
Vet Clin Pathol; 2013 Sep; 42(3):247-9. PubMed ID: 24033798
[No Abstract] [Full Text] [Related]
4. Is It Adverse, Nonadverse, Adaptive, or Artifact?
Pandiri AR; Kerlin RL; Mann PC; Everds NE; Sharma AK; Myers LP; Steinbach TJ
Toxicol Pathol; 2017 Jan; 45(1):238-247. PubMed ID: 27770107
[TBL] [Abstract][Full Text] [Related]
5. Toxicologic Pathology Forum*: Commentary on "Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma".
Patrick DJ; Troth SP
Toxicol Pathol; 2019 Jul; 47(5):574-576. PubMed ID: 31303126
[TBL] [Abstract][Full Text] [Related]
6. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
[TBL] [Abstract][Full Text] [Related]
7. Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop.
Palazzi X; Burkhardt JE; Caplain H; Dellarco V; Fant P; Foster JR; Francke S; Germann P; Gröters S; Harada T; Harleman J; Inui K; Kaufmann W; Lenz B; Nagai H; Pohlmeyer-Esch G; Schulte A; Skydsgaard M; Tomlinson L; Wood CE; Yoshida M
Toxicol Pathol; 2016 Aug; 44(6):810-24. PubMed ID: 27102650
[TBL] [Abstract][Full Text] [Related]
8. Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
Kerlin R; Bolon B; Burkhardt J; Francke S; Greaves P; Meador V; Popp J
Toxicol Pathol; 2016 Feb; 44(2):147-62. PubMed ID: 26704930
[TBL] [Abstract][Full Text] [Related]
9. STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.
Tomlinson L; Ramaiah L; Tripathi NK; Barlow VG; Vitsky A; Poitout-Belissent FM; Bounous DI; Ennulat D
Toxicol Pathol; 2016 Feb; 44(2):163-72. PubMed ID: 26879687
[TBL] [Abstract][Full Text] [Related]
10. ASVCP Guidelines: Principles of Quality Assurance and Standards for Veterinary Clinical Pathology (version 3.0): Developed by the American Society for Veterinary Clinical Pathology's (ASVCP) Quality Assurance and Laboratory Standards (QALS) Committee.
Arnold JE; Camus MS; Freeman KP; Giori L; Hooijberg EH; Jeffery U; Korchia J; Meindel MJ; Moore AR; Sisson SC; Vap LM; Cook JR
Vet Clin Pathol; 2019 Dec; 48(4):542-618. PubMed ID: 31889337
[No Abstract] [Full Text] [Related]
11. Toxicologic Pathology Forum*: Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma.
Gopinath C; Mowat V
Toxicol Pathol; 2019 Jul; 47(5):564-573. PubMed ID: 31291835
[TBL] [Abstract][Full Text] [Related]
12. Deciphering Sources of Variability in Clinical Pathology-It's Not Just about the Numbers.
Everds NE
Toxicol Pathol; 2017 Feb; 45(2):275-280. PubMed ID: 28178898
[TBL] [Abstract][Full Text] [Related]
13. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.
Sellers RS; Nelson K; Bennet B; Wolf J; Tripathi N; Chamanza R; Perron Lepage MF; Adkins K; Laurent S; Troth SP
Toxicol Pathol; 2020 Feb; 48(2):257-276. PubMed ID: 31594486
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for the no observed adverse effect level in safety pharmacology?
Mow T; Andersen NK; Dragsted N; Lassen AB; Laursen M; Bass AS; Valentin JP; Markgraf C; Authier S; Baird TJ; Bhatt S; Traebert M; Leishman DJ; Jones D; Curtis MJ
J Pharmacol Toxicol Methods; 2020 Sep; 105():106917. PubMed ID: 32866658
[TBL] [Abstract][Full Text] [Related]
15. Best practices for clinical pathology testing in carcinogenicity studies.
Young JK; Hall RL; O'Brien P; Strauss V; Vahle JL
Toxicol Pathol; 2011 Feb; 39(2):429-34. PubMed ID: 21297067
[TBL] [Abstract][Full Text] [Related]
16. Harmonization of immunotoxicity guidelines in the ICH process--pathology considerations from the guideline Committee of the European Society of Toxicological Pathology (ESTP) .
Ruehl-Fehlert C; Bradley A; George C; Germann PG; Bolliger AP; Schultee A;
Exp Toxicol Pathol; 2005 Aug; 57(1):1-5. PubMed ID: 16089314
[TBL] [Abstract][Full Text] [Related]
17. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al.
Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE
Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604
[No Abstract] [Full Text] [Related]
18. Recommendations for Clinical Pathology Data Generation, Interpretation, and Reporting in Target Animal Safety Studies for Veterinary Drug Development.
Siska W; Gupta A; Tomlinson L; Tripathi N; von Beust B
Int J Toxicol; 2017; 36(4):293-302. PubMed ID: 28583045
[TBL] [Abstract][Full Text] [Related]
19. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
[TBL] [Abstract][Full Text] [Related]
20. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.
Halpern WG; Ameri M; Bowman CJ; Elwell MR; Mirsky ML; Oliver J; Regan KS; Remick AK; Sutherland VL; Thompson KE; Tremblay C; Yoshida M; Tomlinson L
Toxicol Pathol; 2016 Aug; 44(6):789-809. PubMed ID: 27235322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
